NCCN releases statement addressing ongoing chemotherapy shortages; shares survey results finding more than 90% of cancer centers are impacted
Last Updated: Tuesday, August 22, 2023
A survey by the Best Practices Committee of the National Comprehensive Cancer Network® (NCCN®) shows that 93% of 27 NCCN Member Institution cancer centers report a shortage of carboplatin and 70% report a similar lack of cisplatin, two treatments that are indicated hundreds of times throughout the NCCN Drugs & Biologics Compendium
Advertisement
News & Literature Highlights